Curaleaf's $272 million Aurora bid marks cannabis M&A comeback

Curaleaf Holdings launched an unsolicited $272 million bid for Aurora Cannabis on Tuesday, offering $4 a share, a 45 percent premium, in a cash-and-stock deal that would create the world's largest cannabis company.

"Today, we are putting this proposal directly in the hands of Aurora shareholders," Boris Jordan, chairman and chief executive officer at Curaleaf, said. "We believe our offer provides immediate value and a unique opportunity to participate in the upside of a larger, more diversified global cannabis platform."

The offer values Aurora at $4 per share, comprising 0.3463 Curaleaf subordinate voting shares plus $0.75 in cash, based on Curaleaf's closing price of $9.39 on Aug. 10. Excluding Aurora's $109 million of cash, the premium reaches 110 percent. The combined company would generate about $1.5 billion in annual revenue and $350 million in adjusted EBITDA, with at least $40 million in annual cost savings.

The bid follows years of oversupply, pricing pressure and limited access to capital that hollowed out the sector. If the deal closes, it could trigger a wave of consolidation, with Canopy Growth — valued at $431 million — among the potential targets.

Curaleaf's offer implies a CY2026E adjusted EBITDA multiple of 12 times, more than 68 percent above the comparable Canadian peer average of 7.1 times, according to analyst consensus estimates cited by the company. Aurora's own guidance points to lower revenue and lower adjusted EBITDA in fiscal 2027 than the year just ended, a trajectory Curaleaf argues justifies the premium. Aurora shares added more than 20 percent last week after the bid was first reported.

Aurora's board has formed a special committee to review the offer, though Curaleaf said it has declined to engage meaningfully. The company filed the formal offer and takeover bid circular with Canadian securities regulators and the U.S. Securities and Exchange Commission, and the offer remains open until 5 p.m. Mountain Time on Dec. 1, 2026. Completion requires more than 50 percent of outstanding shares tendered, 66⅔ percent on a fully diluted basis, and customary regulatory approvals.

The deal's structure reflects the sector's financial scars. Aurora's balance sheet as of March 31, 2026, reports share capital of C$7 billion offset by an accumulated deficit of C$6.4 billion, with about 72 percent of that deficit tied to impairments of acquired businesses. Between fiscal 2020 and fiscal 2026, Aurora recognized roughly C$4.65 billion of impairments in continuing operations, and it has booked inventory impairments and "business transformation" costs in each of the past four fiscal years.

Curaleaf, by contrast, generated about $145 million of operating cash flow for the 12 months ended June 30, 2026, and has cut its cost per gram nearly 50 percent since the first quarter of 2024 while lifting average yields almost 90 percent per square foot. Jordan, who has been invested in Curaleaf since 2014, holds an economic interest of about 18 percent, worth $452 million.

The bid is the clearest sign yet that cannabis operators are again seeking scale after a prolonged downturn. Canopy Growth, which trades at $1.02 with a market cap of $431 million, has reduced debt, exited noncore businesses and shifted toward higher-margin medical cannabis while keeping exposure to the U.S. market through Canopy USA — attributes that could make it attractive to a buyer, though its complex corporate structure and U.S. holdings complicate any integration.

Canaccord Genuity is serving as Curaleaf's financial adviser, with Dentons as legal adviser, Kekst CNC on communications and Carson Proxy Advisors on proxy solicitation.

This article is for informational purposes only and does not constitute investment advice.